- Home
- FIVN vs MRUS Comparison
FIVN vs MRUS Comparison
Compare FIVN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- MRUS
- Stock Information
- Founded
- FIVN 2001
- MRUS 2003
- Country
- FIVN United States
- MRUS Netherlands
- Employees
- FIVN N/A
- MRUS N/A
- Industry
- FIVN EDP Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- FIVN Technology
- MRUS Health Care
- Exchange
- FIVN Nasdaq
- MRUS Nasdaq
- Market Cap
- FIVN 2.3B
- MRUS 2.7B
- IPO Year
- FIVN 2014
- MRUS 2016
- Fundamental
- Price
- FIVN $22.32
- MRUS $43.06
- Analyst Decision
- FIVN Strong Buy
- MRUS Strong Buy
- Analyst Count
- FIVN 18
- MRUS 13
- Target Price
- FIVN $54.94
- MRUS $86.85
- AVG Volume (30 Days)
- FIVN 1.9M
- MRUS 872.0K
- Earning Date
- FIVN 05-01-2025
- MRUS 05-07-2025
- Dividend Yield
- FIVN N/A
- MRUS N/A
- EPS Growth
- FIVN N/A
- MRUS N/A
- EPS
- FIVN N/A
- MRUS N/A
- Revenue
- FIVN $1,041,938,000.00
- MRUS $36,133,000.00
- Revenue This Year
- FIVN $12.00
- MRUS $26.81
- Revenue Next Year
- FIVN $10.71
- MRUS $23.85
- P/E Ratio
- FIVN N/A
- MRUS N/A
- Revenue Growth
- FIVN 14.44
- MRUS N/A
- 52 Week Low
- FIVN $21.04
- MRUS $33.19
- 52 Week High
- FIVN $60.81
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- FIVN 30.61
- MRUS 51.15
- Support Level
- FIVN $22.00
- MRUS $33.19
- Resistance Level
- FIVN $24.13
- MRUS $43.46
- Average True Range (ATR)
- FIVN 1.76
- MRUS 3.53
- MACD
- FIVN 0.07
- MRUS 0.34
- Stochastic Oscillator
- FIVN 17.66
- MRUS 80.53
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.